Skip to main content
GHK-Cu Script

Repair research and its supporting cast

The supporting action

Small blood vessels carry the GHK-Cu Script

Collagen gets the leading role in skin claims. The blood-vessel findings in a GHK-Cu wound experiment gave me a different scene to follow.¹

Stage crew moving an ochre scenery panel on a bright rehearsal stage

Wound angiogenesis in mice

The liposomal GHK-Cu wound experiment has a supporting cast worth watching. The 2017 study reported faster scald-wound healing in mice, with healing by 14 days. Its related work with human blood-vessel-lining cells in culture found proliferation increased by 33.1% versus controls, alongside higher expression of the blood-vessel growth signals VEGF and FGF-2.

Blood vessels supply the tissue being rebuilt. I expected collagen-making cells to carry this story; the endothelial cells, which line vessels, gave me a different point of entry. The repair experiment puts growing cells and a growing blood supply in the same scene. The proposed vessel-growth mechanism addresses how the wound closes, beyond a bare count of days.

The formulation matters here: GHK-Cu was enclosed in liposomes, tiny lipid carriers. The living wound result came from mice, while the human cells were in culture. I want those separate settings visible even as the paper connects them. This is a reason to investigate how repair is coordinated, with a human wound-treatment benefit still to be established.

An anatomical illustration of small branching blood vessels beneath repairing skin
Conceptual illustration of blood supply beneath repairing skin. It shows the biological subject, without depicting a study specimen or a measured outcome.

Satisfaction after laser resurfacing

The scene changes with a randomized trial of 13 patients after CO2 laser resurfacing: satisfaction was significantly higher with the GHK-Cu skin-care regimen. Objective redness and wrinkle improvement showed no statistically significant difference between the groups. The paper appeared in 2006.

That uneven ending appeals to me. A person's pleasure in an outcome matters, and the physical measurements matter too; the trial leaves them sitting beside each other. With so few participants, the absence of a significant difference also leaves considerable uncertainty. Declaring the cream a triumph would flatten the result. So would declaring it useless.

The temptation is to write a tidier ending: repaired skin, a satisfied person, a compound that did what was expected. This experiment supplied only some of that. To me, that unfinished quality deserves more attention than an impressive list of molecular effects.

A skin-texture replica beneath a non-contact surface measuring instrument
Illustrated measurement setup with a skin-texture replica. It represents surface measurement, rather than a participant or equipment identified in the trial.

GHK-Cu in skin care

The more flattering story comes from the 71-woman facial-cream study summarized in the skin-regeneration review. Over 12 weeks, women with photoaged skin had reported improvements in firmness, clarity, fine lines and wrinkle depth, with increased skin density and thickness. That is a substantial reason to take copper-peptide skin care seriously.

The publication trail makes me more cautious about the confidence attached to those findings. The familiar trial reaches this site through a review; the research record identifies a conference presentation rather than a readily available primary journal report. A full trial report would let me judge the comparison and measurements, rather than rely on a favourable summary.

The post-laser trial and the facial-cream findings concern different circumstances. Their differences are worth preserving. The benefits essay follows that tension into the personal reports surrounding these ingredients.

A naturally occurring copper peptide

GHK-Cu joins copper to glycine, histidine and lysine, a chain of three amino acids. Copper Tripeptide-1 is its cosmetic ingredient name. The free GHK peptide occurs in plasma, saliva and urine; its reported plasma level falls with age.

That history helps explain the appeal of a restoration story. Something present in younger bodies becomes less abundant; giving it back sounds like an obvious next act. The experiments on collagen-making cells persuade me more than that leap. An age association leaves the cause of slower repair unresolved, and a replacement benefit still needs to be demonstrated.

The research pages follow the more unruly biology: cells making collagen, cells contracting collagen gels, and wound experiments in which the preparation changes along with the peptide. GHK-Cu copper peptide forms deserve separate attention, because GHK and GHK-Cu can arrive in the same conversation while naming different material.

Treatment status

GHK-Cu isn't FDA-approved for treating an illness. Human skin-cream findings cover a much narrower question than systemic treatment, for which completed Phase 2 or Phase 3 human trials are absent. The amounts used in studies provide experimental context; they do not establish a personal treatment plan.